September 10, 2012 (Chevy Chase, Maryland) — Adults should be screened for high triglyceride levels once every five years because of the potential risk of cardiovascular disease and pancreatitis ...
—Analysis of CD4+ and CD8+ T cells from patients with varying lipid levels suggests new role for hypertriglyceridemia in CVD risk. Moderate—but not severe—hypertriglyceridemia has been shown to be ...
Ionis Pharmaceuticals has reported positive topline outcomes from the randomised, global Phase III Essence study of Tryngolza (olezarsen) in individuals with moderate hypertriglyceridemia and, or at ...
“There is increasing evidence that high triglyceride levels represent a cardiovascular risk, and in addition, very high triglyceride level is a risk factor for pancreatitis,” Lars Berglund, MD, PhD, ...
Calculating the ratio between serum triglyceride and apolipoprotein B levels may help rule out patients with hypertriglyceridemia who are at low risk of developing hypertriglyceridemic pancreatitis ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Investigational therapy inhibits production of ...
ATLANTA -- A novel antisense mRNA drug slashed triglycerides in higher risk or moderate hypertriglyceridemia patients and in those with extremely elevated levels from familial chylomicronemia syndrome ...
– Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – – Olezarsen met all key secondary endpoints – – ...
In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary ...
11. Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 23 diabetes: differences and similarities. Eur J Intern Med. 2014;25:407-414. 12. Schwartz DEA, ...
(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) Monday announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia. The study met its primary ...
CARLSBAD, Calif., May 19, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback